Search research articles
Contact Us
Filters
Showing results (1-10 of 43) with videos related to
Page
of 5
Sort By:
Molecular Psychiatry
|
January 8, 2021
Tracing the psychopathology of bipolar disorder to the functional architecture of intrinsic brain activity and its neurotransmitter modulation: a three-dimensional model
Matteo Martino, Paola Magioncalda
Molecular Psychiatry
|
April 16, 2021
A unified model of the pathophysiology of bipolar disorder
Paola Magioncalda, Matteo Martino
Annals of General Psychiatry
|
December 15, 2010
Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report
Michele Fornaro, Matteo Martino
Molecular Psychiatry
|
June 6, 2024
A working model of neural activity and phenomenal experience in psychosis
Matteo Martino, Paola Magioncalda
Molecular Psychiatry
|
December 19, 2023
A three-dimensional model of neural activity and phenomenal-behavioral patterns
Matteo Martino, Paola Magioncalda
Neuropsychiatric Disease and Treatment
|
July 15, 2010
Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management
Michele Fornaro, Matteo Martino
Current Neuropharmacology
|
December 4, 2012
Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Matteo Martino, Giulio Rocchi, Andrea Escelsior, et al.
Expert Opinion on Pharmacotherapy
|
September 6, 2012
The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states?
Michele Fornaro, Matteo Martino, Concetta De Pasquale, et al.
Dialogues in Clinical Neuroscience
|
April 29, 2026
Polarisation of brain dynamics in mania and depression
Matteo Martino, Paola Magioncalda, Benedetta Conio, et al.
Neuropsychiatric Disease and Treatment
|
March 25, 2011
Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
Michele Fornaro, Matteo Martino, Florinda Battaglia, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 43) with videos related to
Sort By:
Page
of 5
Molecular Psychiatry
|
January 8, 2021
Tracing the psychopathology of bipolar disorder to the functional architecture of intrinsic brain activity and its neurotransmitter modulation: a three-dimensional model
Matteo Martino, Paola Magioncalda
Molecular Psychiatry
|
April 16, 2021
A unified model of the pathophysiology of bipolar disorder
Paola Magioncalda, Matteo Martino
Annals of General Psychiatry
|
December 15, 2010
Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report
Michele Fornaro, Matteo Martino
Molecular Psychiatry
|
June 6, 2024
A working model of neural activity and phenomenal experience in psychosis
Matteo Martino, Paola Magioncalda
Molecular Psychiatry
|
December 19, 2023
A three-dimensional model of neural activity and phenomenal-behavioral patterns
Matteo Martino, Paola Magioncalda
Neuropsychiatric Disease and Treatment
|
July 15, 2010
Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management
Michele Fornaro, Matteo Martino
Current Neuropharmacology
|
December 4, 2012
Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Matteo Martino, Giulio Rocchi, Andrea Escelsior, et al.
Expert Opinion on Pharmacotherapy
|
September 6, 2012
The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states?
Michele Fornaro, Matteo Martino, Concetta De Pasquale, et al.
Dialogues in Clinical Neuroscience
|
April 29, 2026
Polarisation of brain dynamics in mania and depression
Matteo Martino, Paola Magioncalda, Benedetta Conio, et al.
Neuropsychiatric Disease and Treatment
|
March 25, 2011
Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
Michele Fornaro, Matteo Martino, Florinda Battaglia, et al.
Page
of 5